Asia-Pacific Indapamide Market Size, Share & Trends Analysis Report by product (1.25 mg and 2.5 mg), By Application (High Blood Pressure, Heart Failure, and Others), and Forecast 2020-2026.
Asia-Pacific indapamide market is estimated to grow significantly at a CAGR of around 3.8% during the forecast period owing to the increasing prevalence of chronic disorders, including hypertension, CVD, and diabetes. The rising incidences of these diseases have been reported in several countries of Asia-Pacific, including China, India, and Singapore. For instance, in India, one in five young adults has high blood pressure, according to the data presented at the 70th Annual Conference of the Cardiological Society of India (CSI) held from November 22nd- 25th 2018. This equals to nearly 80 million adults, which is a significant proportion than the entire UK population. The risk factors for high blood pressure in the country were smoking, tobacco chewing, diabetes mellitus, and high cholesterol. This, in turn, increased the need for hypertension treatment in the region and further encourages the market growth.
The Asia-Pacific indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
The companies which are contributing to the growth of the Asia-Pacific indapamide market include Glenmark Pharmaceuticals Ltd, Shandong Yinfeida Pharmaceutical Co., Ltd., Suzhou Lixin Pharmaceutical Co., Ltd., Merck KGaA, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology
The market study of the Asia-Pacific indapamide market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
The report is intended for indapamide market players, potential entrants and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
1. Asia-Pacific Indapamide Market Research and Analysis by Product
2. Asia-Pacific Indapamide Market Research and Analysis by Application
The Report Covers
Asia-Pacific indapamide market is estimated to grow significantly at a CAGR of around 3.8% during the forecast period owing to the increasing prevalence of chronic disorders, including hypertension, CVD, and diabetes. The rising incidences of these diseases have been reported in several countries of Asia-Pacific, including China, India, and Singapore. For instance, in India, one in five young adults has high blood pressure, according to the data presented at the 70th Annual Conference of the Cardiological Society of India (CSI) held from November 22nd- 25th 2018. This equals to nearly 80 million adults, which is a significant proportion than the entire UK population. The risk factors for high blood pressure in the country were smoking, tobacco chewing, diabetes mellitus, and high cholesterol. This, in turn, increased the need for hypertension treatment in the region and further encourages the market growth.
The Asia-Pacific indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
The companies which are contributing to the growth of the Asia-Pacific indapamide market include Glenmark Pharmaceuticals Ltd, Shandong Yinfeida Pharmaceutical Co., Ltd., Suzhou Lixin Pharmaceutical Co., Ltd., Merck KGaA, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology
The market study of the Asia-Pacific indapamide market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for indapamide market players, potential entrants and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
1. Asia-Pacific Indapamide Market Research and Analysis by Product
2. Asia-Pacific Indapamide Market Research and Analysis by Application
The Report Covers
- Comprehensive research methodology of the Asia-Pacific indapamide market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Asia-Pacific indapamide market.
- Insights about market determinants which are stimulating the Asia-Pacific indapamide market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- ANI Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Ltd.
- Merck KGaA
- Sandoz International GmbH
- Sanofi S.A.
- Shandong Yinfeida Pharmaceutical Co., Ltd.
- Supra Chemicals
- Suzhou Lixin Pharmaceutical Co., Ltd.
- Taj Pharmaceuticals Ltd.
- Torrent Pharmaceuticals Ltd.